Trial Profile

A Single-arm Phase I Clinical Study of GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GT 101 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
Indications Cervical cancer; Malignant melanoma; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors GRIT Biotechnology

Most Recent Events

02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
13 Apr 2026 Planned End Date changed from 31 Dec 2025 to 30 Jun 2026.
29 May 2025 According to a GRIT Biotechnology media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) 42nd annual meeting, which is taking place in Chicago, IL from May 30th to June 3rd.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com